文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

支气管哮喘发病机制中的超敏反应介质和炎症细胞

Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma.

作者信息

Kay A B

出版信息

Eur J Respir Dis Suppl. 1983;129:1-44.


DOI:
PMID:6418559
Abstract

The events which lead to airway narrowing in bronchial asthma are complex. There is little doubt that mast cell-derived pharmacological agents are involved, at least in part, in the initiation of the asthmatic response. However, the inflammatory response which follows mast cell activation might have more relevance to the daily pattern of asthma than the direct effects of mediators on bronchial tissue. Although the IgE mediated release of mediators from sensitized mast cells seems to play a role in pathogenesis in some individuals for some of the time, there is now increasing awareness that mast cells are also triggered by a number of non-immunological stimuli such as exercise/cold air, infection and agents which activate the complement system. Mast cell mediators are either pre-formed within granules or generated from membrane-bound phospholipids. The pre-formed mediators include histamine, various chemotactic peptides including ECF-A and the high molecular weight neutrophil chemotactic factor (NCF), proteases, glycosidases, and the heparin proteoglycan. The membrane-derived agents include the lipoxygenase products (e.g. LTB4 and the "SRS-A" leukotrienes-LTC4/D4/E4), prostaglandins and thromboxane in addition to the PAF-ace-tether (AGEPC). The mediators are diverse both in chemical composition and modes of actions. However, many of the pathological features of bronchial asthma can be explained on the basis of their recognised actions. These can be summarised as follows. Bronchial smooth muscle constriction (histamine, LTC4, LTD4, LTE4, PGF2 alfa, PGD2 and PAF); mucosal oedema (increased permeability--histamine, LTC4, LTD4 and PAF; vasodilation--PGD2, PGE2); mucous plugging (histamine, mono-HETEs and LTC4); inflammatory cell infiltrate (NCF, ECF-A peptides, HETEs, LTB4 and PAF); desquamation of epithelium (proteases, glycosidases, together with lysosomal enzymes, and basic proteins derived from neutrophils and eosinophils). It is likely that mild, easily reversible, episodic asthma is due largely to bronchial smooth muscle contraction whereas the late sustained response is more indicative of an inflammatory response, and dependent on the infiltration of neutrophils and eosinophils as the result of mediators which recruit and activate leucocytes. Much of the evidence for this is based on the demonstration that NCF concentrations in the serum are elevated during early and late phase, antigen- and exercise-induced asthma. Moderate to severe asthma is likely to be largely dependent on a subacute/chronic inflammation of the bronchi with eosinophils and mononuclear cells being prominent.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

导致支气管哮喘气道狭窄的机制很复杂。毫无疑问,肥大细胞衍生的药理介质至少在一定程度上参与了哮喘反应的起始过程。然而,肥大细胞激活后的炎症反应可能比介质对支气管组织的直接作用与哮喘的日常发作模式更相关。虽然IgE介导的致敏肥大细胞释放介质在某些个体的某些时间似乎在发病机制中起作用,但现在越来越意识到肥大细胞也可由多种非免疫刺激触发,如运动/冷空气、感染以及激活补体系统的物质。肥大细胞介质要么预先形成于颗粒内,要么由膜结合磷脂生成。预先形成的介质包括组胺、各种趋化肽,如嗜酸性粒细胞趋化因子A(ECF-A)和高分子量中性粒细胞趋化因子(NCF)、蛋白酶、糖苷酶以及肝素蛋白聚糖。膜衍生介质包括脂氧合酶产物(如白三烯B4(LTB4)和“慢反应物质-A”白三烯-LTC4/D4/E4)、前列腺素、血栓素以及血小板活化因子乙酰醚(AGEPC)。这些介质在化学成分和作用方式上各不相同。然而,支气管哮喘的许多病理特征可根据其已知作用来解释。可总结如下。支气管平滑肌收缩(组胺、LTC4、LTD4、LTE4、前列腺素F2α、前列腺素D2和血小板活化因子);粘膜水肿(通透性增加——组胺、LTC4、LTD4和血小板活化因子;血管舒张——前列腺素D2、前列腺素E2);粘液阻塞(组胺、单羟基二十碳四烯酸和LTC4);炎症细胞浸润(NCF、ECF-A肽、羟基二十碳四烯酸、LTB4和血小板活化因子);上皮细胞脱落(蛋白酶、糖苷酶,以及溶酶体酶,还有源自中性粒细胞和嗜酸性粒细胞的碱性蛋白)。轻度、易于逆转的发作性哮喘很可能主要是由于支气管平滑肌收缩,而后期持续反应更表明是一种炎症反应,并且取决于作为募集和激活白细胞的介质作用结果的中性粒细胞和嗜酸性粒细胞的浸润。对此的许多证据基于以下证明:在早期和晚期、抗原和运动诱发的哮喘期间,血清中NCF浓度升高。中度至重度哮喘很可能在很大程度上取决于支气管的亚急性/慢性炎症,其中嗜酸性粒细胞和单核细胞较为突出。(摘要截选至400字)

相似文献

[1]
Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma.

Eur J Respir Dis Suppl. 1983

[2]
Basic mechanisms in asthma.

Ann Allergy. 1988-5

[3]
The role of lipid mediators in asthma (current views and perspectives).

Allergol Immunopathol (Madr). 1988

[4]
[Mediators of immunologic inflammation of the respiratory tract].

Boll Ist Sieroter Milan. 1988

[5]
Mast cells and asthma. The role of mast cell mediators in the pathogenesis of allergic asthma.

Ann Allergy. 1983-7

[6]
On the role of PGD2 metabolites as markers of mast cell activation in asthma.

Acta Physiol Scand Suppl. 1999-4

[7]
[Physiopathology of asthma: what role for leukotrienes?].

Rev Pneumol Clin. 1997

[8]
[Mast cells and basophils in asthma].

Ann Biol Clin (Paris). 1989

[9]
Leucocytes in asthma.

Immunol Invest. 1988

[10]
[The potential role and mechanism of leukotriene and platelet-activating factor in allergic disease].

Nihon Rinsho. 1993-3

引用本文的文献

[1]
Pathobiology and Regulation of Eosinophils, Mast Cells, and Basophils in Allergic Asthma.

Immunol Rev. 2025-5

[2]
Initiation and Pathogenesis of Severe Asthma with Fungal Sensitization.

Cells. 2021-4-15

[3]
Severe Eosinophilic Asthma.

J Clin Med. 2019-9-2

[4]
Expression of vitamin D receptor in bronchial asthma and its bioinformatics prediction.

Mol Med Rep. 2018-6-13

[5]
Eosinophils in fungus-associated allergic pulmonary disease.

Front Pharmacol. 2013-2-1

[6]
Chronic inflammation and asthma.

Mutat Res. 2009-9-19

[7]
Platelet activating factor as a mediator and therapeutic approach in bronchial asthma.

Inflammation. 2008-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索